AOD-9604 in Chitose — Fat Loss Peptide Research Guide
AOD-9604 research guide for Chitose. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Chitose searching for AOD-9604, the foundational reality is that this compound is distributed via specialist online vendors. This online-only market structure is a genuine benefit for researchers — top vendors distinguish themselves through rigorous testing in ways local stores never could. A legitimate AOD-9604 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. Use this guide to verify vendor quality systematically — the quality evaluation approach outlined here work regardless of your location.
AOD-9604 Mechanisms Explained
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Chitose comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source AOD-9604 — Vendor Guide
Evaluating AOD-9604 vendors begins with the COA: access the batch-specific certificate prior to buying, not after. When reviewing a AOD-9604 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are at acceptable levels for the intended application. Strong quality indicators beyond COA quality: established track record of at least two years, customer service that can discuss analytical methods, and shipping with desiccant and appropriate cold protection. The powdered lyophilised form of AOD-9604 is far superior to liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations break down rapidly even under refrigeration.
Order AOD-9604 — ships to Chitose
COA-verified · International tracking · Research grade
All use of AOD-9604 in Chitose or anywhere is research use only — this compound is not approved for therapeutic human application, and all handling should adhere to research compound handling standards. Temperature excursions — even short periods above −20°C — can partially degrade AOD-9604 without any obvious sign; always maintain cold chain and work with cold-shipped material. Verify the endotoxin level in your AOD-9604 batch COA before any injectable research application — look for results expressed as EU/mg or EU/mL and verify they are within the acceptable range for your research context. Researchers combining AOD-9604 with other compounds should review the available literature for documented interactions before proceeding with any multi-compound protocol.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
